Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Sponsor
Yuhong Li
Study ID
NCT02976896
Phase
PHASE2
Status
Completed

Conditions

  • Esophageal Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib Mesylate — DRUG
    Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.

Study Details

We conduct the phase II clinical trial to further explore the efficacy and safety of Apatinib Mesylate in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments. An exploratory molecular marker analysis will be performed in order to find out the beneficial population of Apatinib Mesylate.

Key Dates

Start date
Aug 31, 2016
Status verified
Feb 2023
Primary completion
Dec 31, 2019
Completion
Dec 31, 2022

Study Design

Enrollment
43 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Mesylate
    Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.

Primary Outcome Measure

Disease control rate [ Time Frame: 6 months ]

Related Studies